Nutromics received FDA breakthrough device designation for its wearable patch designed to track vancomycin levels in real time. The company says the patch could reduce reliance on periodic blood draws used to dose vancomycin, a drug with a narrow therapeutic window and dosing complexity. The breakthrough designation can support more efficient development and review pathways for devices that offer meaningful benefits over existing standards of care. For hospitals, continuous therapeutic drug monitoring could translate into tighter exposure control during treatment of serious infections. Real-time monitoring also raises implementation questions for workflows, calibration, and integration with clinical decision systems, but the FDA’s designation signals regulator interest in advancing less burdensome therapeutic monitoring approaches.